atovaquone has been researched along with 2019 Novel Coronavirus Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alain, T; Arulanandam, R; Azad, T; Bell, JC; Carter-Timofte, ME; Cassin, L; Côté, M; Di Carlo, D; Diallo, JS; Fu, K; Hansen, AL; Hiscott, J; Holm, CK; Idorn, M; Jacobs, D; Jakobsen, MR; Kurmasheva, N; Laroche, G; Maznyi, G; Olagnier, D; Palermo, E; Paludan, SR; Ren, F; Sabourin, LA; Seguin, J; Singaravelu, R; Taha, Z; van der Horst, D; van der Sluis, RM; van Grevenynghe, J | 1 |
| Jacobs, JW; Siddon, AJ | 1 |
| Ahmed, MS; Boys, IN; DeBerardinis, RJ; Eitson, JL; Fan, W; Farag, AB; Kim, SY; Lemoff, A; Mar, K; McDougal, MB; Menendez-Montes, I; Nguyen, NUN; Ohlson, MB; Ortiz, F; Sadek, HA; Schoggins, JW; Solmonson, A; Thet, S; Wang, P; Williams, NS | 1 |
| Floyd, K; Jacob, J; Mena Hernandez, L; Skolnick, J; Suthar, MS; von Beck, T; Zhou, H | 1 |
| Booth, J; Chowdary, P; Khurram, MA; Mohamed, IH; Shetty, S; Yaqoob, M | 1 |
1 review(s) available for atovaquone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Atovaquone; CD4 Lymphocyte Count; CD4-CD8 Ratio; COVID-19; Dideoxynucleosides; Female; Glucocorticoids; Graft Rejection; HIV Infections; HIV-1; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Middle Aged; Mycophenolic Acid; Pneumonia, Pneumocystis; Prednisolone; Raltegravir Potassium; RNA, Viral; SARS-CoV-2; Tacrolimus; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
4 other study(ies) available for atovaquone and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of Concern.
Topics: Antiviral Agents; Atovaquone; COVID-19; Humans; SARS-CoV-2; United States | 2021 |
Concurrent COVID-19 and babesiosis in an older, splenectomized patient.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Atovaquone; Azithromycin; Babesiosis; BNT162 Vaccine; COVID-19; COVID-19 Drug Treatment; Fever; Humans; Leukemia, Myeloid, Acute; Male; Parasitemia; Remission Induction; SARS-CoV-2; Splenectomy | 2021 |
FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.
Topics: Antiviral Agents; Atovaquone; COVID-19; Dihydroorotate Dehydrogenase; Dronedarone; Drug Repositioning; Humans; Mebendazole; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Protease Inhibitors; Purines; SARS-CoV-2 | 2023 |
Atovaquone and Pibrentasvir Inhibit the SARS-CoV-2 Endoribonuclease and Restrict Infection In Vitro but Not In Vivo.
Topics: Animals; Atovaquone; Coronavirus OC43, Human; COVID-19; Endoribonucleases; Mice; SARS-CoV-2 | 2023 |